Trevena Announces Positive Top-line Results from Two Phase 3 Pivotal Efficacy Studies of Intravenous Oliceridine in Moderate-to-Severe Acute Pain
February 21, 2017 07:00 ET
|
Trevena Inc.
– Program is on track for NDA submission in 4Q 2017 – – OLINVOTM to be the proprietary brand name for oliceridine –– Company to host conference call and webcast at 8:00...
Trevena Completes Enrollment of Phase 3 APOLLO Pivotal Efficacy Trials of Oliceridine for Moderate-to-Severe Acute Pain
January 04, 2017 07:00 ET
|
Trevena Inc.
KING OF PRUSSIA, Pa., Jan. 04, 2017 (GLOBE NEWSWIRE) -- Trevena, Inc. (NASDAQ:TRVN) today announced that it has completed enrollment of its Phase 3 APOLLO-1 and APOLLO-2 pivotal efficacy studies of...